Moberg Pharma AB (publ) (STO:MOB)
Sweden · Delayed Price · Currency is SEK 9.01
-0.09 (-1.04%)
At close: Dec 5, 2025
Moberg Pharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 12.5 | 9.81 | - | 0.21 | - | 33.66 | Upgrade | |
Revenue Growth (YoY) | 42.27% | - | - | - | - | -33.33% | Upgrade |
Cost of Revenue | 5.96 | 3.5 | - | - | - | - | Upgrade |
Gross Profit | 6.54 | 6.32 | - | 0.21 | - | 33.66 | Upgrade |
Selling, General & Admin | 31.85 | 28.97 | 24.86 | 21.07 | 18.51 | 22.1 | Upgrade |
Research & Development | 303.02 | 302.23 | 3.66 | 1.18 | 3.45 | 5.54 | Upgrade |
Other Operating Expenses | -0.27 | - | -0.61 | -1.52 | -2.23 | -3.8 | Upgrade |
Operating Expenses | 334.59 | 331.2 | 27.91 | 20.72 | 19.73 | 23.83 | Upgrade |
Operating Income | -328.05 | -324.89 | -27.91 | -20.52 | -19.73 | 9.83 | Upgrade |
Interest Expense | -0.19 | -0.23 | -0.26 | -0.07 | -0.13 | -1.02 | Upgrade |
Interest & Investment Income | 5.17 | 4.58 | 2.3 | 0.79 | - | 0.02 | Upgrade |
Currency Exchange Gain (Loss) | 0.06 | 0.06 | 0.45 | 0.29 | - | 0.21 | Upgrade |
Other Non Operating Income (Expenses) | - | - | - | - | -0.11 | -0.08 | Upgrade |
EBT Excluding Unusual Items | -323.02 | -320.47 | -25.42 | -19.51 | -19.97 | 8.96 | Upgrade |
Pretax Income | -323.02 | -320.47 | -25.42 | -19.51 | -19.97 | 8.96 | Upgrade |
Income Tax Expense | -65.23 | -65.36 | -4.33 | -3.8 | -3.75 | 2.15 | Upgrade |
Earnings From Continuing Operations | -257.79 | -255.11 | -21.09 | -15.71 | -16.22 | 6.81 | Upgrade |
Earnings From Discontinued Operations | - | - | - | - | 23.59 | -1.05 | Upgrade |
Net Income to Company | -257.79 | -255.11 | -21.09 | -15.71 | 7.37 | 5.76 | Upgrade |
Minority Interest in Earnings | - | - | - | - | 0.13 | 0.11 | Upgrade |
Net Income | -257.79 | -255.11 | -21.09 | -15.71 | 7.49 | 5.87 | Upgrade |
Net Income to Common | -257.79 | -255.11 | -21.09 | -15.71 | 7.49 | 5.87 | Upgrade |
Net Income Growth | - | - | - | - | 27.73% | -70.71% | Upgrade |
Shares Outstanding (Basic) | 47 | 38 | 16 | 8 | 4 | 2 | Upgrade |
Shares Outstanding (Diluted) | 47 | 38 | 16 | 8 | 4 | 2 | Upgrade |
Shares Change (YoY) | 41.02% | 138.46% | 109.19% | 76.28% | 127.45% | 0.34% | Upgrade |
EPS (Basic) | -5.51 | -6.74 | -1.33 | -2.07 | 1.74 | 3.12 | Upgrade |
EPS (Diluted) | -5.51 | -6.74 | -1.33 | -2.07 | 1.70 | 3.07 | Upgrade |
EPS Growth | - | - | - | - | -44.56% | -71.07% | Upgrade |
Free Cash Flow | -15.83 | -16.47 | -33.21 | -16.84 | -15.3 | -10.41 | Upgrade |
Free Cash Flow Per Share | -0.34 | -0.43 | -2.09 | -2.22 | -3.55 | -5.50 | Upgrade |
Gross Margin | 52.35% | 64.37% | - | 100.00% | - | 100.00% | Upgrade |
Operating Margin | -2625.04% | -3311.46% | - | -9911.59% | - | 29.21% | Upgrade |
Profit Margin | -2062.80% | -2600.26% | - | -7589.37% | - | 17.43% | Upgrade |
Free Cash Flow Margin | -126.70% | -167.87% | - | -8136.23% | - | -30.93% | Upgrade |
EBITDA | -327.41 | -324.33 | -26.96 | -19.62 | -19.73 | 9.88 | Upgrade |
EBITDA Margin | - | - | - | - | - | 29.36% | Upgrade |
D&A For EBITDA | 0.64 | 0.56 | 0.95 | 0.9 | 0 | 0.05 | Upgrade |
EBIT | -328.05 | -324.89 | -27.91 | -20.52 | -19.73 | 9.83 | Upgrade |
EBIT Margin | - | - | - | - | - | 29.21% | Upgrade |
Effective Tax Rate | - | - | - | - | - | 23.96% | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.